U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Lung Large Cell Carcinoma

MedGen UID:
163172
•Concept ID:
C0854977
•
Neoplastic Process
Synonyms: Recurrent Large Cell Carcinoma of Lung; Recurrent Large Cell Carcinoma of the Lung; Recurrent Large Cell Lung Carcinoma; Relapsed Large Cell Carcinoma of Lung; Relapsed Large Cell Carcinoma of the Lung; Relapsed Large Cell Lung Carcinoma

Definition

The reemergence of large cell lung carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Lung Large Cell Carcinoma

Professional guidelines

PubMed

Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J, Modrego A, Zeaiter A, Kahatt C, Alfaro V, Jimenez-Aguilar E, Mazarico JM, Paz-Ares L
Future Oncol 2021 Jun;17(18):2279-2289. Epub 2021 Mar 19 doi: 10.2217/fon-2020-1212. PMID: 33736462
On the pharmacogenetics of non-small cell lung cancer treatment.
Santarpia M, Rolfo C, Peters GJ, Leon LG, Giovannetti E
Expert Opin Drug Metab Toxicol 2016;12(3):307-17. Epub 2016 Feb 17 doi: 10.1517/17425255.2016.1141894. PMID: 26761638
Diagnosis and treatment of neuroendocrine lung tumors.
Sánchez de Cos Escuín J
Arch Bronconeumol 2014 Sep;50(9):392-6. Epub 2014 Mar 28 doi: 10.1016/j.arbres.2014.02.004. PMID: 24685201

Recent clinical studies

Etiology

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators
Lancet Oncol 2017 Jan;18(1):42-51. Epub 2016 Dec 5 doi: 10.1016/S1470-2045(16)30565-4. PMID: 27932068Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Lung-MAP--framework, overview, and design principles.
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA
Chin Clin Oncol 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. PMID: 26408303
Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.
Vijayvergia N, Shah PC, Denlinger CS
J Natl Compr Canc Netw 2015 Sep;13(9):1151-61. doi: 10.6004/jnccn.2015.0140. PMID: 26358799Free PMC Article
Large-cell neuroendocrine carcinoma of the lung.
Fernandez FG, Battafarano RJ
Cancer Control 2006 Oct;13(4):270-5. doi: 10.1177/107327480601300404. PMID: 17075564

Diagnosis

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium, Birkbak NJ, McGranahan N, Swanton C
Nature 2023 Apr;616(7957):553-562. Epub 2023 Apr 13 doi: 10.1038/s41586-023-05776-4. PMID: 37055640Free PMC Article
Lung-MAP--framework, overview, and design principles.
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA
Chin Clin Oncol 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02. PMID: 26408303
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article
Diagnosis and treatment of neuroendocrine lung tumors.
Sánchez de Cos Escuín J
Arch Bronconeumol 2014 Sep;50(9):392-6. Epub 2014 Mar 28 doi: 10.1016/j.arbres.2014.02.004. PMID: 24685201
Large-cell neuroendocrine carcinoma of the lung.
Fernandez FG, Battafarano RJ
Cancer Control 2006 Oct;13(4):270-5. doi: 10.1177/107327480601300404. PMID: 17075564

Therapy

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL, Weiss J, Schroeder MR, Ward S, Grigoriadis K, Shahpurwalla A, Litchfield K, Puttick C, Biswas D, Karasaki T, Black JRM, Martínez-Ruiz C, Bakir MA, Pich O, Watkins TBK, Lim EL, Huebner A, Moore DA, Godin-Heymann N, L'Hernault A, Bye H, Odell A, Roberts P, Gomes F, Patel AJ, Manzano E, Hiley CT, Carey N, Riley J, Cook DE, Hodgson D, Stetson D, Barrett JC, Kortlever RM, Evan GI, Hackshaw A, Daber RD, Shaw JA, Aerts HJWL, Licon A, Stahl J, Jamal-Hanjani M; TRACERx Consortium, Birkbak NJ, McGranahan N, Swanton C
Nature 2023 Apr;616(7957):553-562. Epub 2023 Apr 13 doi: 10.1038/s41586-023-05776-4. PMID: 37055640Free PMC Article
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD
J Clin Oncol 2017 Jan;35(1):56-62. Epub 2016 Oct 31 doi: 10.1200/JCO.2016.69.1378. PMID: 28034064Free PMC Article
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators
Lancet Oncol 2017 Jan;18(1):42-51. Epub 2016 Dec 5 doi: 10.1016/S1470-2045(16)30565-4. PMID: 27932068Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article

Prognosis

Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives.
Schegoleva AA, Khozyainova AA, Fedorov AA, Gerashchenko TS, Rodionov EO, Topolnitsky EB, Shefer NA, Pankova OV, Durova AA, Zavyalova MV, Perelmuter VM, Denisov EV
Cell Physiol Biochem 2021 Mar 10;55(S2):29-48. doi: 10.33594/000000340. PMID: 33687819
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD
J Clin Oncol 2017 Jan;35(1):56-62. Epub 2016 Oct 31 doi: 10.1200/JCO.2016.69.1378. PMID: 28034064Free PMC Article
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators
Lancet Oncol 2017 Jan;18(1):42-51. Epub 2016 Dec 5 doi: 10.1016/S1470-2045(16)30565-4. PMID: 27932068Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Large-cell neuroendocrine carcinoma of the lung.
Fernandez FG, Battafarano RJ
Cancer Control 2006 Oct;13(4):270-5. doi: 10.1177/107327480601300404. PMID: 17075564

Clinical prediction guides

Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D
Mol Cancer Ther 2020 Nov;19(11):2235-2244. Epub 2020 Sep 23 doi: 10.1158/1535-7163.MCT-20-0116. PMID: 32967924
Radiomics for Response and Outcome Assessment for Non-Small Cell Lung Cancer.
Shi L, He Y, Yuan Z, Benedict S, Valicenti R, Qiu J, Rong Y
Technol Cancer Res Treat 2018 Jan 1;17:1533033818782788. doi: 10.1177/1533033818782788. PMID: 29940810Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ
Sci Transl Med 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459. PMID: 26311731Free PMC Article
Pharmacogenomics and gemcitabine.
Rosell R, Cobo M, Isla D, Camps C, Massuti B
Ann Oncol 2006 May;17 Suppl 5:v13-16. doi: 10.1093/annonc/mdj942. PMID: 16807441

Recent systematic reviews

Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.
Naheed S, Holden C, Tanno L, Pattini L, Pearce NW, Green B, Jaynes E, Cave J, Ottensmeier CH, Pelosi G
BMJ Open 2022 Mar 3;12(3):e041961. doi: 10.1136/bmjopen-2020-041961. PMID: 35241462Free PMC Article
Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Chen D, Mao Y, Wen J, She Y, Zhu E, Zhu F, Zhang Y, Fan M, Chen C, Chen Y
Ann Thorac Surg 2019 Sep;108(3):945-954. Epub 2019 Mar 23 doi: 10.1016/j.athoracsur.2019.02.045. PMID: 30914285
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
Tang H, Wang S, Xiao G, Schiller J, Papadimitrakopoulou V, Minna J, Wistuba II, Xie Y
Ann Oncol 2017 Apr 1;28(4):733-740. doi: 10.1093/annonc/mdw683. PMID: 28200038Free PMC Article
Risk factors for recurrence in patients with resected N1 non-small cell lung cancer - a systematic review and meta-analysis.
Luo H, Qiao L, Liang N, Zhang J
J BUON 2015 May-Jun;20(3):791-9. PMID: 26214632
Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.
Wang J, Chen J, Chen X, Wang B, Li K, Bi J
PLoS One 2011;6(12):e28844. Epub 2011 Dec 14 doi: 10.1371/journal.pone.0028844. PMID: 22194927Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...